FIELD: medicine.
SUBSTANCE: invention relates to the treatment of pulmonary hypertension. A method for the treatment or prevention of pulmonary hypertension in a patient who needs it includes the administration of therapeutically effective amount of tacrolimus or its pharmaceutically acceptable salt in a combination with PDE5 inhibitor. In this case, tacrolimus or its pharmaceutically acceptable solvate is administered for clinical deterioration delay, where the ratio of tacrolimus or its pharmaceutically acceptable solvate and PDE5 inhibitor is selected in such a way that a combinatory index less than 1.2 is reached. In this case, the patient is experiencing at least one of (a) change in one or several hemodynamics parameters indicating the improvement of pulmonary hypertension condition in the direction of a more normal level compared to the initial level; (b) increase in the ability for physical activity compared to the initial level; (c) reduction in Borg dyspnea index compared to the initial level; (d) improvement of one or several parameters of life quality compared to the initial level; (e) transition to a lower WHO functional class, and (f) reduction in natriuretic peptide levels in plasma compared to the initial level.
EFFECT: invention provides for reduction in toxicity and reduction in side effects.
8 cl, 1 dwg, 1 tbl, 2 ex
